November 23, 2011

Medtronic iPro®2 CGM Approved by FDA

From the News Wire: 

MINNEAPOLIS – November 22, 2011 – Medtronic, Inc. (NYSE:MDT) today announced the Food and Drug Administration (FDA) approval of iPro®2, a next generation Professional continuous glucose monitoring (CGM) system and the latest in a series of recent diabetes technology approvals and innovations from the company. iPro2 simplifies Professional CGM and enables healthcare providers to obtain a more complete picture of glucose control for the patients they treat.  Professional CGM is used by healthcare providers to reveal low (hypoglycemia) and high (hyperglycemia) glucose excursions that can lead to the dangerous health complications of diabetes.  These excursions often go unnoticed with traditional A1C tests and standard glucose meter measurements.